MedPath

Identification of Vulnerability Factors in the Course of Pemphigus Patients

Not Applicable
Conditions
Pemphigus
Dermatological Disease
Registration Number
NCT02237313
Lead Sponsor
University Hospital, Rouen
Brief Summary

The bullous pemphigoid treatment is based on corticosteroids continued for several years. Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at later stages of disease progression. Our hypothesis is that these episodes of vulnerability may be under four kinds of factors that may be connected to the plurality of the history of these patients, and the resources they can mobilize throughout this experience, generating inequality in management and "work" around the disease.

Detailed Description

The originality of the project lies in its multidisciplinary approach (dermatology, psychology, sociology). No such study has yet been carried out in the pemphigus who has been the subject of a very small number of works in sociology or psychology. The only studies are studies of quality of life with no longitudinal follow-up. The perspective of qualitative and quantitative data, sociological and psychological approaches, should allow more innovative and adapted to the medico-social and psychological care of patients with pemphigus approaches. The purpose of this study is to identify the determinants leading to moments of vulnerability in the course of patients with pemphigus in order to be able to offer preventive or corrective actions to improve the experience of the disease.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Patient major

  • Patients with pemphigus vulgaris, diagnosed on a combination of:

    1. clinical signs and
    2. histological image above basal epithelial detachment with intra acantholysis,
    3. direct immunofluorescence showing deposition of Immunoglobulin G and / or C3 to the surface of keratinocytes
  • Join a social security scheme

  • patient has been informed and have signed consent to participate in the study

Exclusion Criteria
  • Person placed under judicial protection,
  • Patient without liberty by administrative or judicial decision,
  • Patient participating in another trial for the duration of monitoring.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
analysis of vulnerability factors12 months

evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire

Secondary Outcome Measures
NameTimeMethod
assessment of anxiety, uncertainty, fear, coping strategies6 months

assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire

analysis of vulnerability factors6 months

evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire

Trial Locations

Locations (9)

Hôpital Avicenne

🇫🇷

Bobigny, France

CHU de Clermont-Ferrand Hôpital d'Estaing

🇫🇷

Clermont-Ferrand, France

CH du Mans

🇫🇷

le Mans, France

CHRU de Lille Hôpital Claude Huriez

🇫🇷

Lille, France

Hôpital La Timone, Assistance publique hôpitaux de Marseille-Aix

🇫🇷

Marseille, France

Hôpital Haut-Lévêque

🇫🇷

Pessac, France

Centre hospitalier de Cornouaille

🇫🇷

Quimper, France

Hôpital Robert Debré, chu de Reims

🇫🇷

Reims, France

University Hospital of Rouen

🇫🇷

Rouen, France

Hôpital Avicenne
🇫🇷Bobigny, France
Catherine PROST-SQUARCIONI, Professor
Contact
1 48 95 77 07
catherine.prost@avc.aphp.fr
Catherine PROST-SQUARCIONI, professor
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.